Regeneron Pharmaceuticals (REGN) FCF Margin (2009 - 2026)

Regeneron Pharmaceuticals' FCF Margin history runs 18 years deep, the most recent figure standing at 23.53% for Q1 2026.

• In Q1 2026, FCF Margin fell 341.0% year-over-year to 23.53%; the TTM figure through Mar 2026 stood at 27.57% (up 555.0% YoY), while the FY2025 annual figure was 28.45%, up 265.0% from the prior year.
• FCF Margin was 23.53% for Q1 2026 at Regeneron Pharmaceuticals, down from 23.74% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 3919.8% in Q1 2022 to a low of 9.48% in Q2 2024.
• Historically, FCF Margin has averaged 345.89% across 5 years, with a median of 26.94% in 2025.
• The sharpest annual moves came in 2022 and 2023: FCF Margin surged 389632 bps in 2022, then plunged 388219 bps in 2023.
• A 5-year view of FCF Margin shows it stood at 1567.7% in 2022, then sank by 98 bps to 24.41% in 2023, then rose by 15 bps to 28.06% in 2024, then fell by 15 bps to 23.74% in 2025, then retreated by 1 bps to 23.53% in 2026.
• The last three FCF Margin figures came in at 23.53% (Q1 2026), 23.74% (Q4 2025), and 30.57% (Q3 2025), per Business Quant data.